Chiroscience Selects Two Cancer Drugs

10 March 1997

At an analysts' meeting last week, the UK biotechnology companyChiroscience revealed that it has selected two matrix metalloproteinase inhibitors, D1927 and D2163, to enter Phase I clinical trials, which will begin in the fourth quarter of this year.

In preclinical models of cancer, both drugs demonstrated a high level of selectivity and efficacy. This latest development means that Chiroscience now has four compounds in or entering clinical trials, while the addition of cancer therapies to the product pipeline is expected to substantially increase the value of the company, said analysts. More news on Chiroscience's drug development activities will be published in next week's Marketletter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight